Diagnosis and treatment of type 2 diabetes and other disorders
AssigneeMerck Sharp & Dohme Corp.
InventorsYun-Ping Zhou, Jing Li, Weizhen Wu, Jin Shang, John R. Thompson, Nancy A. Thornberry
Life of this patent
Estimating the term…
Abstract
The present application features the use of the somatostatin subtype 3 receptor (SST3) as a target for affecting insulin secretion and for diagnosing diabetes related disorders. Glucose stimulated insulin secretion was found to be stimulated by knocking down expression of SST3 and through the use of a SST3 selective antagonist.
Claims13
A method for increasing insulin secretion in patient in need thereof comprising the step of administer to said patient an effective amount of a somatostatin subtype 3 receptor (SST3) antagonist or an agent that reduces expression of SST3.
A method of screening for a compound affecting at least one of insulin secretion or glucose uptake comprising the steps of:
- (a) identifying a compound binding to, or inhibiting, the activity or expression of SST3;
- and
- (b) determining the ability of said compound identified in said step (a) to affect at least on of one:
- insulin secretion or glucose uptake.
A method of determining progression of diabetes comprising the steps of:
- (a) using a selective SSTR3 ligand to measure β-cell mass and (b) determining whether there is a low or a decrease in β-cell mass.
Dependencies are inferred from the claim text.